Shares of Esperion Therapeutics (NASDAQ:ESPR) have been assigned a consensus recommendation of “Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Two analysts have rated the stock with a sell rating, five have given a hold rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $91.42.
Several research analysts have commented on the stock. UBS set a $90.00 price target on shares of Esperion Therapeutics and gave the stock a “neutral” rating in a research note on Wednesday, February 21st. JPMorgan Chase reissued a “neutral” rating and set a $65.00 price target (up from $55.00) on shares of Esperion Therapeutics in a research note on Wednesday, February 21st. BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 9th. ValuEngine raised shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Northland Securities lifted their price target on shares of Esperion Therapeutics from $100.00 to $121.00 and gave the stock a “buy” rating in a research note on Thursday, April 19th.
In other news, Director Roger S. Newton sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, March 29th. The shares were sold at an average price of $72.37, for a total value of $1,809,250.00. Following the transaction, the director now owns 639,682 shares in the company, valued at $46,293,786.34. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 14.50% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP grew its holdings in shares of Esperion Therapeutics by 348.6% in the first quarter. Quantbot Technologies LP now owns 1,588 shares of the biopharmaceutical company’s stock worth $114,000 after purchasing an additional 1,234 shares during the last quarter. Raymond James Financial Services Advisors Inc. bought a new position in shares of Esperion Therapeutics in the fourth quarter worth approximately $222,000. BB&T Securities LLC bought a new position in shares of Esperion Therapeutics in the fourth quarter worth approximately $263,000. First Mercantile Trust Co. grew its holdings in shares of Esperion Therapeutics by 56.0% in the fourth quarter. First Mercantile Trust Co. now owns 4,233 shares of the biopharmaceutical company’s stock worth $279,000 after purchasing an additional 1,519 shares during the last quarter. Finally, Creative Planning bought a new position in shares of Esperion Therapeutics in the fourth quarter worth approximately $314,000. Hedge funds and other institutional investors own 91.38% of the company’s stock.
ESPR traded up $1.61 on Monday, reaching $42.21. The company had a trading volume of 1,179,700 shares, compared to its average volume of 1,015,934. The company has a market capitalization of $1.13 billion, a P/E ratio of -6.05 and a beta of 2.52. Esperion Therapeutics has a 52-week low of $40.26 and a 52-week high of $42.82.
Esperion Therapeutics (NASDAQ:ESPR) last announced its earnings results on Wednesday, May 2nd. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.17). During the same quarter last year, the firm earned ($1.80) EPS. research analysts anticipate that Esperion Therapeutics will post -5.91 EPS for the current year.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.